Waters Corp. (WAT) Tops Q4 EPS by 22c, Revenues Beat; Offers FY19 EPS Mid-Point Above Consensus

Waters Corp. (NYSE: WAT) reported Q4 EPS of $2.87, $0.22 better than the analyst estimate of $2.65. Revenue for the quarter came in at $715 million versus the consensus estimate of $704.25 million.

ris O’Connell, Chairman and Chief Executive Officer of Waters Corporation, commented, “We were pleased to end 2018 on a high note, with improving performance in our key market categories, products, and geographies. This fourth quarter improvement was highlighted by strength in our pharmaceutical category, TA product line, and China. We are looking forward to building on this momentum in 2019 and expect to benefit from our new product cycle, headlined by yesterday’s BioAccord system launch.”

GUIDANCE:

Waters Corp. sees FY2019 EPS of $9.20-$9.45, versus the consensus of $9.21.

Waters Corp. sees Q1 2019 EPS of $1.65-$1.75, versus the consensus of $1.73.

For earnings history and earnings-related data on Waters Corp. (WAT) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• INVO Fertility (IVF) Tops Q2 EPS by 105c